| dc.contributor.author | Baeten, JM | |
| dc.contributor.author | Lingappa, J | |
| dc.contributor.author | Beck, I | |
| dc.contributor.author | Frenkel, LM | |
| dc.contributor.author | Pepper, G | |
| dc.contributor.author | Wald, A | |
| dc.contributor.author | Fife, KH | |
| dc.contributor.author | Were, E | |
| dc.contributor.author | Mugo, N | |
| dc.contributor.author | Sanchez, J | |
| dc.contributor.author | Essex, M | |
| dc.contributor.author | Makhema, J | |
| dc.contributor.author | Kiarie, J | |
| dc.contributor.author | Farquhar, C | |
| dc.contributor.author | Corey, L | |
| dc.date.accessioned | 2013-06-12T12:11:37Z | |
| dc.date.available | 2013-06-12T12:11:37Z | |
| dc.date.issued | 2011-01 | |
| dc.identifier.citation | J Infect Dis. 2011 Jan 1;203(1):117-21. | en |
| dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/21148504 | |
| dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/32282 | |
| dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024584/ | |
| dc.description.abstract | Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance. | en |
| dc.language.iso | en | en |
| dc.publisher | Univesity of Nairobi | en |
| dc.title | Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. | en |
| dc.type | Article | en |
| local.publisher | Department of Medicine | en |
